Latest Tax Rebates News

Page 1 of 16
Actinogen Medical’s shares have been suspended while it completes analysis of additional data from its pivotal XanaMIA Alzheimer’s trial. The company expects trading to resume no later than 19 November unless the results announcement comes first.
Ada Torres
Ada Torres
17 Nov 2026
Neurizon says it has removed its remaining Obsidian convertible notes while targeting $6.3 million in new equity ahead of the pivotal NUZ-001 ALS readout. The funding plan reduces immediate conversion uncertainty, but the proposed Share Purchase Plan and possible future facility drawdown leave execution questions open.
Ada Torres
Ada Torres
5 Nov 2026
Noxopharm has secured a $1.5 million placement and agreed to convert $3.78 million of shareholder notes as it prepares to test SOF-SKN in cutaneous lupus patients. The funding eases an immediate cash constraint, but the package also brings substantial dilution and remains partly subject to shareholder approval.
Ada Torres
Ada Torres
2 Nov 2026
Strategic Elements has moved its EdgeiQ platform closer to commercial mining pilots while Energy Ink progresses towards a system-level demonstration. The ASX-listed venture developer ended September with $3.918 million in cash and an estimated 4.32 quarters of funding at the quarter’s spending rate.
Sophie Babbage
Sophie Babbage
30 Oct 2026
Recce Pharmaceuticals has cleared an active-comparator design for its pivotal Australian diabetic foot infection trial while an independent review of Indonesian Phase 3 data approaches. The biotech ended the quarter with A$1.04 million in cash, alongside expected tax rebates and unused financing facilities.
Victor Sage
Victor Sage
30 Oct 2026
Epiminder has enrolled its 100th patient in the DETECT US epilepsy study ahead of schedule, while maintaining A$65.1 million in cash and no borrowings. The company says those reserves can fund clinical development and commercialisation work well into 2028.
Victor Sage
Victor Sage
30 Oct 2026
Sparc Technologies has moved its graphene additive business from testing towards commercial adoption, with a first ecosparc® delivery to a tier 1 coatings manufacturer and more than 20 active qualification programs. The September quarter also delivered hydrogen progress and fresh funding, but the company reported only 1.14 quarters of cash coverage before subsequent receipts.
Sophie Babbage
Sophie Babbage
30 Oct 2026
Anson Resources has secured the final major approval for its planned 10,000 tpa Green River lithium plant, while reporting independently confirmed battery-grade product and approximately US$406.5 million of conditional Utah incentives. The project has moved closer to financing, but the incentives are post-performance and Anson says further funding is still required.
Maxwell Dee
Maxwell Dee
29 Oct 2026
Turnstone Resources has completed portfolio-wide magnetic surveys in Sweden and begun reviewing strategic options for its German potash assets, while its September cash balance covered less than one quarter of reported outgoings. The ASX-listed explorer also secured A$1.1 million in placement commitments and expects lower corporate costs ahead.
Maxwell Dee
Maxwell Dee
28 Oct 2026
Amplia Therapeutics is preparing the next stage of narmafotinib’s pancreatic cancer development as its ACCENT trial nears completion and a Lilly collaboration broadens the drug’s potential into lung cancer. The biotech ended September with $20.8 million in cash, rising to $25.6 million pro forma after an October R&D tax refund.
Victor Sage
Victor Sage
28 Oct 2026
Actinogen Medical has received an A$10.84 million R&D tax rebate, leaving it with A$21.9 million in pro forma cash and no debt just weeks before its pivotal Alzheimer’s readout. The company says topline XanaMIA results remain due in mid-November.
Ada Torres
Ada Torres
26 Oct 2026
Amplia Therapeutics has received an A$4.78 million refundable R&D tax rebate, giving the clinical-stage biotechnology company additional cash to advance its FAK inhibitor programs. The funds will support multiple narmafotinib trials and related research, including studies involving Lilly.
Victor Sage
Victor Sage
22 Oct 2026

Browse the archive

Full archive